|
Pathogen (Target Population)
|
Vaccine Envisaged
|
Annualized Present Value of Potential Health Benefits (IME Units)
|
Annualized Present Value of Expenditures on Vaccines Necessary to Achieve Potential Health Benefits ($ millions)
|
|
Rotavirue
(Infants, 0–6 months)
|
Attenuated high passage bovine rotavirus
|
521,852
|
853
|
|
Attenuated low passage bovine rotavirus
|
450,795
|
655
|
|
Rhesus monkey rotavirus
|
450,795
|
656
|
|
Salmonella typhi
(Children; young adults at risk; travelers from developed countries to endemic areas)
|
Attenuated ga1E mutant S. typhi strain TY21a
|
431,471
|
358
|
|
Aromatic amino acid dependent strains of S. typhi
|
194,745
|
152
|
|
Shigella spp.
(Infants at birth; elderly for epidemic strains)
|
Probably plasmid mediated outer membrane protein invasion determinant (there are a small number of promising options needing investigation to determine best approach)
|
222,096
|
92
|
|
Streptococcus A
(Children, < 3–4 years)
|
Synthetic M protein segment (excluding portions cross-reacting with human tissue)
|
180,513
|
554
|
|
Streptococcus pneumoniae
(Infants)
|
Conjugated polysaccharides, polyvalent
|
1,363,943
|
1,310
|
|
Vibrio cholera
(Children, especially < 2 years)
|
Genetically defined live mutant V. cholerae (A−B+ or A−B−) with respect to toxin subunit synthesis
|
94,986
|
24
|
|
Inactivated antigens
|
65,548
|
44
|
|
Yellow fever virus
(Young children)
|
Attenuated live virus produced in cell culture
|
11,127
|
93
|
